Franzén L, Funegård U, Ericson T, Henriksson R
Department of Oncology, University Hospital, Umeå, Sweden.
Eur J Cancer. 1992;28(2-3):457-62. doi: 10.1016/s0959-8049(05)80076-0.
Radiotherapy of tumours in the head and neck region usually involves the salivary glands in the treatment volume with ensuing dryness and discomfort. In the present study, a prospective evaluation of the same patients were performed before, during radiotherapy and 6, 12 and 18 months after the end of treatment. Three different groups were outlined, one receiving doses not exceeding 45 Gy, another 47-52 Gy and a third group treated with doses over 64 Gy. All but one of the patients receiving doses less than 52 Gy showed a recovery of secretion beginning after 2 months with a continuous improvement of the salivary flow up to 18 months. Doses exceeding 64 Gy caused irreversibly depressed parotid function in the vast majority of glands. The subjective experience of discomfort with dry mouth was not at all correlated to the initial flow rate. Treatment with unilateral technique and doses below 52 Gy caused just no or slight dryness and 3 out of 4 patients with bilateral involvement of the glands displayed problem with subjective dryness even after 18 months. Doses over 64 Gy with one gland involved had only slight dryness, however, patients with both glands affected showed severe problems with dryness. It has to be emphasised that there were relatively large interindividual differences with respect to salivary flow and discomfort of dryness. It is obvious that these patients need a careful dose planning and a close follow up with co-operation between radiotherapeutists and dentists.
头颈部肿瘤的放射治疗通常会使治疗区域内的唾液腺受到照射,进而导致口干和不适。在本研究中,对同一组患者在放疗前、放疗期间以及治疗结束后的6个月、12个月和18个月进行了前瞻性评估。研究划分了三个不同的组,一组接受的剂量不超过45 Gy,另一组为47 - 52 Gy,第三组接受的剂量超过64 Gy。接受剂量低于52 Gy的患者中,除一人外,其余患者在2个月后唾液分泌开始恢复,唾液流量持续改善直至18个月。超过64 Gy的剂量导致绝大多数腺体的腮腺功能出现不可逆的抑制。口干不适的主观感受与初始唾液流速完全无关。采用单侧技术且剂量低于52 Gy的治疗仅导致无或轻微口干,4名双侧腺体受累的患者中,即使在18个月后仍有主观口干问题。一个腺体受累且剂量超过64 Gy时仅有轻微口干,然而,两个腺体均受累的患者则出现严重的口干问题。必须强调的是,在唾液流量和口干不适方面存在较大的个体差异。显然,这些患者需要精心的剂量规划以及放疗师和牙医之间密切合作的密切随访。